Fred Eshelman, Pharm.D., has been unanimously appointed to the board of directors and named chairman of the board. Jay Shepard, Srinivas Akkaraju, M.D., Ph.D., and Robert Hoffman have resigned from the board of directors.
Aravive (ARAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aravive, Inc. (ARAV), a clinical-stage biopharmaceutical company, announced that the first patient has been dosed in an investigator-sponsored Phase 1/2 clinical trial of the company’s GAS6/AXL inhibitor AVB-500 in combination with PD-L1 inhibitor avelumab in patients with advanced urothelial carcinoma (UC). The study is being led by Abhishek Tripathi, M.D., Assistant Professor of Medicine, Section of hematology/oncology at the University of Oklahoma Stephenson Cancer Center. “Locally advanced or metastatic urothelial carcinoma is an aggressive cancer with poor long-term survival,” said Dr. Tripathi.
HOUSTON, May 06, 2020 -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening.
Aravive (ARAV) closed at $13.82 in the latest trading session, marking a +0.88% move from the prior day.
In the latest trading session, Aravive (ARAV) closed at $11.96, marking no change from the previous day.
bluebird bio (BLUE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020Company announces clinical trial.
HOUSTON, May 12, 2020 -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening.
Aravive (ARAV) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Is (ARAV) Outperforming Other Medical Stocks This Year?
HOUSTON, Feb. 25, 2020 -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that it will present at Cowen and Company's 40th Annual.
Top Ranked Momentum Stocks to Buy for April 20th
Aravive, Inc. (ARAV), a clinical-stage biopharmaceutical company, announced that AVB-500 improves anti-tumor effects when combined with the anti-angiogenic bevacizumab or the PARP inhibitor olaparib in pre-clinical uterine cancer models. Additional research also showed that inhibition of GAS6/AXL signaling with AVB-500 induces ‘BRCA-ness’, increasing response to platinum and PARPi in a preclinical model of ovarian cancer.
Outlook Therapeutics (OTLK) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Aravive (ARAV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Aravive, Inc. (ARAV), a clinical-stage biopharmaceutical company, and WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced a strategic collaboration agreement granting Aravive the right to use the proprietary WuXiBody™ platform to develop high-affinity bispecific antibodies for a target implicated in cancer and fibrosis. Aravive and WuXi Biologics will collaborate to discover antibodies against CCN2, a multidomain protein also known as connective tissue growth factor (CTGF).
As of late, it has definitely been a great time to be an investor in Aravive.
Aravive, Inc. (Aravive) (ARAV) today announced that the independent Data Monitoring Committtee (DMC) has reviewed the open-label data following the first 28-day treatment cycle for the three patients in each of the two 15 mg/kg dosing cohorts of the Phase 1b portion of the Phase 1b/Phase 2 clinical trial of AVB-500 in patients with platinum-resistant recurrent ovarian cancer (PROC) and unanimously recommended the study continue as planned with enrollment of patients into the 20mg/kg dose cohorts. On November 20, 2019, Aravive reported data from the first 31 patients treated at the 10mg/kg dose supporting a relationship between AVB-500 blood levels and anti-tumor response, confirming the company’s strategy to investigate higher doses of AVB-500, specifically 15 and 20 mg/kg every two weeks.